Market By Prescription Types, Therapeutics, End-users And Geography | Forecast 2019-2027
Triton predicts the global ophthalmic drugs market to rise in terms of revenue and grow at a CAGR of 4.47% from the forecast years 2019 to 2027. The market was assessed to be worth $26192.27 million in the year 2018 and is predicted to generate a revenue of approximately $38792.45 million by the year 2027.
Ophthalmic refers to the eye and the drugs designed to treat eye-related ailments are called ophthalmic drugs. The administration of the drug is done by the installation of an ointment, a cream or a liquid drop preparation in the conjunctival sac. The exact amount and strength of the drug are selected, and the medication is instilled into the eye or eyes as directed. Ophthalmic drugs are widely used to treat conditions like cataracts, glaucoma, diabetic retinopathy, and other ophthalmic disorders. The pioneering of novel ocular drug delivery approaches in the market has encouraged the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders.
Report scope can be customized per your requirements. Request For Customization
Ophthalmic drugs therapeutics are used extensively for various purposes. Diabetic macular edema (abbreviated as DME) refers to the thickening of the retina within the two-disc diameters of the center of the macula, which primarily occurs from the changes in the retinal microvascular that is compromised of the blood-retinal barrier. Eye cancer can be referred to as the growth of the abnormal cells inside or around the eye that leads to the development of a tumor within the eye.
Diabetic retinopathy can be referred to as a diabetic complication that affects the eyesight of the individuals. Diabetic retinopathy affects the blood vessels inside the retina. Retinal vein blockage may be defined as a small vein’s blockage that executes the function of carrying out blood from the retina. Age-related macular degeneration is one of the most common eye conditions and the primary cause of vision loss among the population aged 50 and above.
Conjunctivitis, referred to as “pink eye” may be defined as the inflammation of the conjunctiva; the conjunctiva is a thin & transparent layer that covers the inside of the eyelids and the white part of the eye. Dry eye occurs when tears are not of exact consistency or when the eyes do not produce tears correctly and evaporate too fast. Glaucoma can be referred to as the group of eye diseases that damage the optic nerve, and that leads to vision loss. Keratitis is the inflammation of the cornea. Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD).
The Triton report on the ophthalmic drugs market has discussed the value chain outlook, the key insights regarding the industry, Porter’s five force analysis, and the vendor scorecard.
Market drivers such as the advancement in technology, the growing geriatric population worldwide, rising expenditure in healthcare and the rising occurrence of eye syndromes are advancing the market growth globally. However, restraints like delays in drug approvals and brand patent expirations are expected to create hurdles in the growth of the market. The rise in the rates of ophthalmic treatments and emerging economies are creating opportunities for the market to grow in the projected period.
To get detailed insights on segments, Download Sample Report
Geographies that have been covered in the global ophthalmic drugs market are:
• North America: the United States and Canada
• Europe: the United Kingdom, Germany, France, Italy, Spain, Russia.
• Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand.
• Latin America: Brazil, Mexico and Rest of Latin America
• The Middle East & Africa: the United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East & Africa
The ophthalmic drugs market has been segmented into:
• By prescription type:
O Prescription ophthalmic drugs
O OTC (Over-the-Counter) drugs
• By therapeutics:
O Diabetic macular edema
O Eye cancer
O Diabetic retinopathy
O Retinal vein occlusion
O Age-related macular degeneration
O Conjunctivitis
O Dry eye
O Glaucoma
O Keratitis
O Geographic Atrophy
O Lens opacification and intraocular lens
• By End-Users:
O Hospitals
O Eye clinics ophthalmic drugs
O Diagnostics centers ophthalmic drugs
O Patient ophthalmic drugs
The key players in the ophthalmic drugs market include Santen Pharmaceutical Co., Ltd, SENJU Pharmaceutical Co., Ltd, Roche Holding AG, Abbott Laboratories, GlaxoSmithKline, Allergan, Inc., Cipla Pharmaceuticals, Sun Pharmaceuticals Industries, Ltd., Pfizer, Inc., EyeGate Pharmaceuticals, Merck & Co., Johnson and Johnson, EyeMed, Regeneron, Valeant, Novartis AG, Apollo Endosurgery, Akorn and Bayer.
The strategic analysis for each of the companies in the ophthalmic drugs market is detailed in the report. The company market share helps with the information of the key market players and their share in the market.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT1. GLOBAL
OPHTHALMIC DRUGS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. VALUE
CHAIN OUTLOOK
2.3. VENDOR
SCORECARD
2.4. KEY
INSIGHTS
2.5. PORTER’S
FIVE FORCES OUTLOOK
2.5.1. BARGAINING
POWER OF BUYERS
2.5.2. BARGAINING
POWER OF SUPPLIER
2.5.3. THREATS
OF NEW ENTRANTS
2.5.4. THREATS
OF SUBSTITUTES
2.5.5. COMPETITIVE
RIVALRY
2.6. MARKET
DRIVERS
2.6.1. ADVANCEMENT
IN TECHNOLOGY
2.6.2. GROWING
GERIATRIC POPULACE WORLDWIDE
2.6.3. RISING
EXPENDITURE IN HEALTHCARE
2.6.4. RISING
OCCURRENCE OF EYE SYNDROMES
2.7. MARKET
RESTRAINTS
2.7.1. DELAY
IN DRUG APPROVALS
2.7.2. BRAND
PATENT EXPIRATIONS
2.8. MARKET
OPPORTUNITIES
2.8.1. RISE
IN THE RATES OF OPHTHALMIC TREATMENT
2.8.2. RISING
OPPORTUNITIES IN EMERGING ECONOMIES
3. OPHTHALMIC
DRUGS MARKET OUTLOOK – BY PRESCRIPTION TYPES
3.1. PRESCRIPTION
OPHTHALMIC DRUGS
3.2. OTC
(OVER-THE-COUNTER DRUGS)
4. OPHTHALMIC
DRUGS MARKET OUTLOOK – BY THERAPEUTICS
4.1. DIABETIC
MACULAR EDEMA
4.2. EYE
CANCER
4.3. DIABETIC
RETINOPATHY
4.4. RETINAL
VEIN OCCLUSION
4.5. AGE-RELATED
MACULAR DEGENERATION
4.6. CONJUNCTIVITIS
4.7. DRY
EYE
4.8. GLAUCOMA
4.9. KERATITIS
4.10.
GEOGRAPHIC ATROPHY
4.11.
LENS OPACIFICATION AND
INTRAOCULAR LENS
5. OPHTHALMIC
DRUGS MARKET OUTLOOK – BY END-USERS
5.1. HOSPITALS
5.2. EYE
CLINICS OPHTHALMIC DRUGS
5.3. DIAGNOSTIC
CENTERS OPHTHALMIC DRUGS
5.4. PATIENT
OPHTHALMIC DRUGS
6. OPHTHALMIC
DRUGS MARKET – REGIONAL OUTLOOK
6.1. NORTH
AMERICA
6.1.1. COUNTRY
ANALYSIS
6.1.1.1. UNITED
STATES
6.1.1.2. CANADA
6.2. EUROPE
6.2.1. COUNTRY
ANALYSIS
6.2.1.1. GERMANY
6.2.1.2. UNITED
KINGDOM
6.2.1.3. RUSSIA
6.2.1.4. FRANCE
6.2.1.5. ITALY
6.2.1.6. SPAIN
6.3. ASIA-PACIFIC
6.3.1. COUNTRY
ANALYSIS
6.3.1.1. CHINA
6.3.1.2. INDIA
6.3.1.3. SOUTH
KOREA
6.3.1.4. JAPAN
6.3.1.5. AUSTRALIA
& NEW ZEALAND
6.3.1.6. ASEAN
COUNTRIES
6.4. MIDDLE
EAST & AFRICA
6.4.1. COUNTRY
ANALYSIS
6.4.1.1. SAUDI
ARABIA
6.4.1.2. TURKEY
6.4.1.3. UNITED
ARAB EMIRATES
6.4.1.4. SOUTH
AFRICA
6.4.1.5. REST
OF MIDDLE EAST & AFRICA
6.5. LATIN
AMERICA
6.5.1. COUNTRY
ANALYSIS
6.5.1.1. MEXICO
6.5.1.2. BRAZIL
6.5.1.3. REST
OF LATIN AMERICA
7. COMPETITIVE
LANDSCAPE
7.1. ABBOTT
LABORATORIES
7.2. JOHNSON
AND JOHNSON
7.3. ALLERGAN,
INC.
7.4. BAYER
7.5. REGENERON
7.6. AKORN
7.7. VALEANT
7.8. EYEMED
7.9. SENJU
PHARMACEUTICAL CO., LTD
7.10.
MERCK & CO.
7.11.
PFIZER, INC.
7.12.
NOVARTIS AG
7.13.
GLAXOSMITHKLINE
7.14.
EYEGATE PHARMACEUTICALS
7.15.
ROCHE HOLDING AG
7.16.
APOLLO ENDOSURGERY
7.17.
SANTEN PHARMACEUTICAL CO., LTD
7.18.
SUN PHARMACEUTICALS
INDUSTRIES, LTD.
7.19.
CIPLA PHARMACEUTICALS
8. METHODOLOGY
AND SCOPE
8.1. RESEARCH
SCOPE
8.2. SOURCES
OF DATA
8.3. RESEARCH
METHODOLOGY
TABLE 1 GLOBAL OPHTHALMIC DRUGS MARKET BY
GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE
ELDERLY
TABLE 3 EYE DRUGS GONE OFF-PATENT
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY
PRESCRIPTION TYPE 2019-2027 ($ MILLION)
TABLE 5 FDA-APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 6 DETAILS OF SOME KEY PRESCRIPTION DRUGS
TABLE 7 OPHTHALMIC DRUG PRODUCTS FOR
OVER-THE-COUNTER HUMAN USE
TABLE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY
THERAPEUTICS 2019-2027 ($ MILLION)
TABLE 9 SYMPTOMS, TREATMENT AND RECOVERY TIME
FOR DIABETIC MACULAR EDEMA
TABLE 10 SYMPTOMS AND TREATMENT FOR EYE CANCER
TABLE 11 GLOBAL OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 12 GLOBAL OPHTHALMIC DRUGS MARKET BY
GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY
COUNTRIES 2019-2027 ($ MILLION)
TABLE 14 UNITED STATES OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 15 UNITED STATES HOSPITAL FACT SHEET, 2016
TABLE 16 CANADA OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 17 EXTRAPOLATION OF PREVALENCE RATE OF
GLAUCOMA BY COUNTRIES
TABLE 18 EUROPE OPHTHALMIC DRUGS MARKET BY
COUNTRIES 2019-2027 ($ MILLION)
TABLE 19 GERMANY OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 20 UK OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 21 RUSSIA OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 22 NUMBER OF HOSPITALS IN RUSSIA, 2015
TABLE 23 FRANCE OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 24 ITALY OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 25 SPAIN OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 26 ASIA-PACIFIC OPHTHALMIC DRUGS MARKET BY
COUNTRIES 2019-2027 ($ MILLION)
TABLE 27 CHINA OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 28 INDIA OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 29 HUMAN RESOURCE NEEDS FOR EYE CARE IN INDIA
TABLE 30 SOUTH KOREA OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 31 JAPAN OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 32 AUSTRALIA & NEW ZEALAND OPHTHALMIC
DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 33 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS
MARKET BY COUNTRIES 2019-2027 ($ MILLION)
TABLE 34 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS
MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 35 LATIN AMERICA OPHTHALMIC DRUGS MARKET BY
COUNTRIES 2019-2027 ($ MILLION)
TABLE 36 LATIN AMERICA OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
TABLE 37 MEXICO OPHTHALMIC DRUGS MARKET BY END-USERS
2019-2027 ($ MILLION)
FIGURE 1 THE POPULATION OF PEOPLE AGED 65 AND OVER
WILL DOUBLE IN THE NEXT 25 YEARS (MILLION)
FIGURE 2 PROJECTIONS FOR THE PROPORTION OF
GERIATRIC (60+) POPULATION IN 2015, 2030 AND 2050
FIGURE 3 HEALTHCARE EXPENDITURE CATARACT SURGERIES
ON THE RISE
FIGURE 4 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015,
2020 AND 2050 (MILLION)
FIGURE 5 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN
2013, 2020 AND 2040 (MILLION)
FIGURE 6 GLOBAL OPHTHALMIC DRUGS MARKET IN
PRESCRIPTION OPHTHALMIC DRUGS 2019-2027 ($ MILLION)
FIGURE 7 GLOBAL OPHTHALMIC DRUGS MARKET IN OTC 2019-2027
($ MILLION)
FIGURE 8 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC
MACULAR EDEMA 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE
CANCER 2019-2027 ($ MILLION)
FIGURE 10 DIABETIC RETINOPATHY PREVALENCE IN THE US
2011 AND 2030 (MILLION)
FIGURE 11 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC
RETINOPATHY 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL OPHTHALMIC DRUGS MARKET IN RETINAL
VEIN OCCLUSION 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL OPHTHALMIC DRUGS MARKET IN AGE-RELATED
MACULAR DEGENERATION 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL OPHTHALMIC DRUGS MARKET IN
CONJUNCTIVITIS 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL OPHTHALMIC DRUGS MARKET IN DRY EYE
2019-2027 ($ MILLION)
FIGURE 16 GLOBAL OPHTHALMIC DRUGS MARKET IN GLAUCOMA
THERAPEUTICS 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL OPHTHALMIC DRUGS MARKET IN KERATITIS 2019-2027
($ MILLION)
FIGURE 18 GLOBAL OPHTHALMIC DRUGS MARKET IN GEOGRAPHIC
ATROPHY 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL OPHTHALMIC DRUGS MARKET IN LENS
OPACIFICATION AND INTRAOCULAR LENS 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL OPHTHALMIC DRUGS MARKET IN HOSPITALS
OPHTHALMIC DRUGS 2019-2027 ($ MILLION)
FIGURE 21 TOTAL OPHTHALMIC CARE HOSPITAL IN UNITED
STATES
FIGURE 22 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CLINICS
OPHTHALMIC DRUGS 2019-2027 ($ MILLION)
FIGURE 23 EYE DISEASES CASES IN MILLION ABOVE AGE OF 40
IN AMERICA
FIGURE 24 GLOBAL OPHTHALMIC DRUGS MARKET IN DIAGNOSTIC
CENTERS OPHTHALMIC DRUGS 2019-2027 ($ MILLION)
FIGURE 25 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES
ABOVE AGE 40 IN US (IN MILLION)
FIGURE 26 GLOBAL OPHTHALMIC DRUGS MARKET IN PATIENTS
OPHTHALMIC DRUGS 2019-2027 ($ MILLION)
FIGURE 27 NORTH AMERICA OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 28 US POPULATION AGES 65 AND OLDER, 1960 TO 2060
(MILLION)
FIGURE 29 US OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 30 CANADA OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 31 PREVALENCE RATE OF RETINAL DISORDERS IN
CANADA, 2016
FIGURE 32 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT
IN CANADA
FIGURE 33 EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 34 DEVELOPMENT OF THE EUROPEAN POPULATION AGED
65 AND OVER, 2010, 2025 AND 2050 (MILLION)
FIGURE 35 PROPORTION OF OPTOMETRISTS AND OPTICIANS IN
EUROPEAN COUNTRIES, 2015
FIGURE 36 GERMANY OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 37 POPULATION AGES 65 AND ABOVE (% OF TOTAL)
FIGURE 38 UK OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 39 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT
LOSS IN THE UK (MILLION)
FIGURE 40 RUSSIA OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 41 POPULATION AGED 65 AND ABOVE IN FRANCE (% OF
TOTAL)
FIGURE 42 FRANCE OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 43 POPULATION AGED 65 AND ABOVE IN ITALY (% OF
TOTAL)
FIGURE 44 ITALY OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 45 POPULATION AGED 65 AND ABOVE IN SPAIN (% OF
TOTAL)
FIGURE 46 SPAIN OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 47 ASIA-PACIFIC OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 48 CHINA OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 49 INDIA OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 50 SOUTH KOREA OPHTHALMIC DRUGS MARKET 2019-2027
($ MILLION)
FIGURE 51 NUMBER OF YEARS FOR PERCENTAGE, AGED 65 AND
ABOVE IN TOTAL POPULATION TO TRIPLE
FIGURE 52 POPULATION AGED 65 AND ABOVE IN JAPAN (% OF
TOTAL)
FIGURE 53 JAPAN OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 54 POPULATION AGED 65 AND ABOVE IN AUSTRALIA (%
OF TOTAL)
FIGURE 55 AUSTRALIA AND NEW ZEALAND OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 56 ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 57 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE 58 SAUDI ARABIA OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 59 TURKEY OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 60 UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 61 SOUTH AFRICA OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 62 REST OF MIDDLE EAST & AFRICA OPHTHALMIC
DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 63 LATIN AMERICA OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 64 AGING POPULATION IN COLOMBIA 1950-2050 (IN
THOUSANDS)
FIGURE 65 MEXICO OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 66 PERCENTAGE OF PEOPLE AGED 65 AND ABOVE,
MEXICO (1950-2050)
FIGURE 67 PROPORTION OF DIRECT COST OF EYE DISEASE IN
MEXICO, BY PAYER
FIGURE 68 BRAZIL OPHTHALMIC DRUGS MARKET 2019-2027 ($
MILLION)
FIGURE 69 REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET
2019-2027 ($ MILLION)